Metal-Based Drugs

Metal-Based Drugs / 1999 / Article

Open Access

Volume 6 |Article ID 487928 | https://doi.org/10.1155/MBD.1999.135

John A. Kuykendall, III, Hugh Simmons, III, Henry J. Irving, Mark A. Wear, Paul G. Sorenson, Linda G. Tipton, Kenchasha M. Maddox, Elsie L. Williams, Van Anh Pham-Tran, Chassie Credit, Israt L. Chowdhury, Shaheen Khan, J. Brooks Tipton, William M. Willingham, John R. J. Sorenson, "Radioprotectant Activity of 5-Diethylsulfonamoylsalicylatocopper(II) in Gamma Irradiated Mice", Metal-Based Drugs, vol. 6, Article ID 487928, 7 pages, 1999. https://doi.org/10.1155/MBD.1999.135

Radioprotectant Activity of 5-Diethylsulfonamoylsalicylatocopper(II) in Gamma Irradiated Mice

Received17 Mar 1999
Accepted31 Mar 1999

Abstract

Survival and changes in mean body mass of whole-body irradiated mice were determined to examine the radioprotectant activity of 5-diethylsulfonamoylsalicylatocopper(II) [Cu(II) (5-DESS)]. One of four groups of 25 female C57BL/6 mice were treated subcutaneously (sc)with 0, 10, 20, 40, 60, 80, 100, or 120 μmol Cu(II)(5- DESS)/kg of body mass 3 hours before exposure to 8.0 Gy, gamma irradiation. In this paradigm, doses of Cu(II)(5- DESS) increased survival up to 92% above vehicle-treated control mice (P = 0.008) . Mean body mass determinations revealed that mice treated with 80 to 120 μmol Cu(II)(5-DESS)/kg of body mass exhibited a smaller decrease in body mass than other complex-treated groups. These results support the hypothesis that Cu(II)(5-DESS) is an effective radioprotectant.

Copyright © 1999 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


More related articles

 PDF Download Citation Citation
 Order printed copiesOrder
Views32
Downloads32
Citations

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.